Eledon Pharmaceuticals Inc Dossier - Source-backed chat

Eledon Pharmaceuticals Inc

ELDNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.97

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.44Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $197.9M

Enterprise Value $191.1M

Shares Outstanding 81.3M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Eledon Pharmaceuticals is a high-conviction clinical-stage biotechnology company focused on developing tegoprubart, a next-generation anti-CD40L monoclonal antibody. Tegoprubart targets the costimulatory CD40/CD40L pathway to provide non-lymphocyte depleting, less toxic immunosuppression. The investment thesis is anchored on tegoprubart's potential to replace highly toxic standard-of-care calcineurin inhibitors (like tacrolimus) in kidney and islet cell transplantation. Recent clinical data demonstrating 100% insulin independence in Type 1 Diabetes patients undergoing islet transplantation, combined with upcoming Phase 3 trials in kidney transplantation, positions Eledon as a major disruptor in the multi-billion dollar transplant market.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$9.00

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0015%

Tegoprubart encounters safety hurdles or fails to meet primary endpoints in upcoming Phase 3 trials. Regulatory delays postpone the initiation of the Phase 3 kidney transplant study, and the company faces severe dilution risks as its cash runway approaches mid-2027 without a partner.

Base CaseCentral scenario

$8.0060%

Eledon successfully initiates its Phase 3 kidney transplant trial by late 2026 following positive regulatory feedback. The company maintains its cash runway into Q2 2027, successfully raising additional capital at favorable terms as clinical milestones are met. Tegoprubart continues to show a durable safety profile and improved graft function in long-term extension studies.

Bull CaseUpside scenario

$12.0025%

Tegoprubart achieves superior efficacy and safety in Phase 3 kidney transplant trials, leading to rapid FDA approval and widespread adoption as the new standard of care. The islet cell transplant program successfully transitions to a sponsored study, unlocking a functional cure narrative for Type 1 Diabetes. Strategic partnerships or a premium acquisition by a major pharmaceutical company materialize.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong clinical proof-of-concept with 100% insulin independence achieved in 10 Type 1 Diabetes patients treated with tegoprubart following islet transplantation.
Tegoprubart targets the well-validated CD40/CD40L pathway, offering a potentially safer, less toxic alternative to standard-of-care tacrolimus.
Orphan Drug designations granted by the FDA for prevention of allograft rejection in pancreatic islet cell, liver, and kidney transplantation, as well as ALS treatment.
Robust pipeline optionality spanning kidney, islet cell, liver, and xenotransplantation, alongside neurodegenerative diseases (ALS).

Key Investment Risks

Clinical development risk: Tegoprubart is a single-asset pipeline, making the company highly vulnerable to any clinical or regulatory setbacks.
Financial risk: As a clinical-stage biotech with no commercial revenues, Eledon will require substantial additional capital to fund Phase 3 trials, presenting dilution risks.
Historical hurdles: The drug previously faced challenges in meeting primary endpoints in certain historical studies, despite showing strong safety benefits.

Thesis Invalidation Triggers

Failure to reach an agreement with the FDA on the Phase 3 kidney transplant trial design.
Unfavorable long-term safety or efficacy data from the Phase 2 BESTOW extension study.
Inability to secure additional financing or strategic partnerships before the cash runway expires in 2Q 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.